Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 277 participants.
Also called NCT02730455
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 277 participants
- Sponsor
- Registry
-
NCT02730455 -
2015-004783-11
-
- Other papers using this trial's data
- Natalizumab in acute ischemic stroke (ACTION II): A randomized, placebo-controlled trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Germany, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT02730455. Randomized; quadruple masking; primary purpose treatment. Start 2016-07-18 (actual); primary completion 2017-11-20 (actual). Results posted on 2019-01-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke
- Acronym
- ACTION2
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- natalizumab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Biogen
Record details
- Record id
cardio:ct-nct02730455- Content hash
cb4a277d1fa66f081794d8d33e65dabf089d4c0c2c3abc16e0bcab2f11c06071